Navigation Links
Xanodyne Raises $50 Million in Equity Financing to Support Emerging Product Portfolio
Date:10/29/2009

NEWPORT, Ky., Oct. 29 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today the completion of $50 million in equity financing. The round was led by Longitude Capital with participation from new investors Skandia and Silver Point Capital. Other current investors that participated in the financing include MPM Capital, LLC, AIG Investments' sponsored funds, Perseus-Soros Biopharmaceutical Fund, Blue Chip Venture Company, HealthCare Ventures, LLC, and Union Springs, LLC. Aquilo Partners, L.P., a life science investment bank, acted as the exclusive placement agent for the financing.

Michael J. Valentino, President and CEO commented, "I am extremely pleased to have secured additional financial resources which will be used to support our ongoing development and commercialization strategy for our emerging product portfolio."

In June 2009, Xanodyne received Food and Drug Administration (FDA) approval for Zipsor(TM) (diclofenac potassium) Liquid Filled Capsules, a new treatment option for relief of mild to moderate acute pain in adults (18 years of age or older). Zipsor was launched nationally to physicians and patients in September.

In addition, the company expects FDA action soon on Lysteda(TM) (formerly XP12B), an oral tranexamic acid product under priority review. If approved, Lysteda would be the first and only oral therapeutic agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.

Valentino added, "The continued commitment from our investor groups allows us to remain focused on aggressively executing our product commercialization plans and optimizing the other assets in our portfolio."

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integra
'/>"/>

SOURCE Xanodyne Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Light Sciences Oncology Raises $40.1 Million in Series C Financing
6. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
7. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
8. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
9. Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. SynergEyes, Inc. Raises $13.3 Million in Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
(Date:8/27/2015)... According to a new market research report "Medical Lifting ... ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End User ... Medical Lifting Sling Market is poised to reach USD 706.0 Million ... of 11.4 % from 2015 to 2020. , ... ables and 65 F igures ...
(Date:8/27/2015)... BIRMINGHAM, Ala. , Aug. 27, 2015 ... Integrated Outpatient Pharmacy Provider (IOPP™) is expanding ... launch of a medication-focused transition of care ... program, named "RxCare Management," provides hospitals with ... improve hospital performance measures that have been ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2
... 2011 Nektar Therapeutics (Nasdaq: NKTR ) ... 2 clinical study of NKTR-102 in patients with metastatic ... Cancer Symposium in San Francisco, California.  NKTR-102 is a ... conjugate technology, and is being developed in multiple tumor ...
... The Board of the European Fine Chemicals ... to ratify the proposal of the US Food and Drug ... the help of EFCG and US industry representatives, to deliver ... (GDUFA). GDUFA requires the FDA to commit to ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this software allows businesses to track product movement from beginning to end. , Businesses ...
(Date:8/28/2015)... ... August 28, 2015 , ... CARF ... its adolescent residential, counseling, day treatment and intensive family based services. , By ... for quality and its pursuit of excellence. As a nonprofit charity for more ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... Researchers ... comprehensive information on two new duals programs: Rhode Island Integrated Care Initiative, ... Idaho’s partnership to revamp Blue Cross of Idaho’s D-SNP. The database also ...
(Date:8/28/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... in order to ease the stress on the atmosphere, and lessen the number and ... the real cause of global warming and urges them to look into his studies ...
Breaking Medicine News(10 mins):Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2
... Enhanced design now features End-of-Life capability and longer ... LLC, a leading supplier of batteries for implantable ... enhanced Lithium Carbon Monofluoride (Li/CFx) battery technology with ... the market. The technology includes a proprietary new ...
... Remote Magnetic Navigation prominently featured on the HRS 2009 ... STXS ) said today that the Heart Rhythm ... in which its Niobe system is either featured or ... presentations include new efficacy data on the use of ...
... takes shared responsibility to a whole new level. ... saving $2 trillion in healthcare costs over the next ... is within our grasp.Blue Shield of California has long ... We are pleased that these groups are embracing the ...
... emerging pandemic of a new strain of influenza A (H1N1) ... , Researchers from the MRC Centre for Outbreak Analysis and ... World Health Organisation and public health agencies in Mexico, have ... Their key findings are as follows: , , ...
... Drug Information Association (DIA), the premiere neutral, global, multidisciplinary association ... the launch of its new online Career Center--a highly targeted ... ... Horsham, PA, USA (Vocus) May 11, 2009 -- The ...
... on Kidz-Med Thermofocus(R) 5-in-1WESTON, Fla., May 11 American ... revenue results for the first quarter ending March 31, ... with net sales of $263,603 for the first quarter ... for the first quarter of 2008.The sales increase was ...
Cached Medicine News:Health News:EaglePicher Medical Power Announces New Li/CFx Battery Technology 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 2Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 3Health News:Stereotaxis' Market Leadership Highlighted at Heart Rhythm 2009 4Health News:Swine flu: Early findings about pandemic potential reported in new study 2Health News:Drug Information Association (DIA) Launches New Online Career Center 2Health News:Drug Information Association (DIA) Launches New Online Career Center 3Health News:American Scientific Resources, Inc. Releases First Quarter Revenues 2
... We offer a complete ... bringing laboratorians state-of-the-art monoclonal and ... the detection of enteric pathogens ... includes products for Clostridium difficile, ...
... is a second-generation rapid ELISA for the detection ... fecal specimens. The test utilizes highly specific antibodies ... the more common toxin A+ samples, but also ... perform, produces no indeterminates and provides results in ...
... products for autoimmune testing feature single-well ANA ... as specific reflex tests including dsDNA, and ... (Ro), SS-B (La), Scl-70 and Jo-1. In ... full line of products for Cardiolipins (IgA, ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
Medicine Products: